Monte Rosa Therapeutics, Inc.

Name: Monte Rosa Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

GLUENasdaqCIK 1826457HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$9.0m, Q2 FY2026

Operating income−$49.1m, Q2 FY2026

Net income−$43.4m, Q2 FY2026

Monte Rosa Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	1.1	4.7	9.2	60.6	84.9	23.2	12.8	2.8	4.2	9.0
Research and development	$m	28.3	27.1	27.0	28.1	27.6	38.9	32.2	30.7	36.7	42.0	44.1	48.0
Operating income	$m	(37.0)	(34.9)	(34.9)	(32.6)	(26.5)	13.0	44.0	(15.6)	(33.0)	(49.7)	(50.0)	(49.1)
Income tax	$m	0.2	(0.0)	0.1	0.3	0.1	2.2	0.8	1.2	(3.2)	0.1	0.1	0.2
Net income	$m	(34.9)	(33.3)	(32.0)	(30.3)	(23.9)	13.4	46.9	(12.3)	(27.1)	(46.1)	(44.5)	(43.4)
Diluted EPS	$ per share	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Balance sheet

Cash and equivalents$90.1m, Q2 FY2026

Shareholders' equity$487.3m, Q2 FY2026

Monte Rosa Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	59.1	128	99.8	109	126	224	78.5	69.4	208	130	160	90.1
Current assets	$m	183	236	199	278	251	377	332	299	402	393	678	631
Total assets	$m	252	304	267	344	315	439	393	360	460	449	736	691
Current liabilities	$m	22.6	46.6	41.3	42.3	41.6	157	59.2	41.9	61.4	64.2	71.0	59.7
Total liabilities	$m	67.6	125	114	119	110	216	118	91.5	214	216	215	204
Shareholders' equity	$m	185	179	153	225	205	223	275	268	246	233	522	487

Cash flow

Operating cash flow−$44.1m, Q2 FY2026

Capital expenditure$4.7m, Q2 FY2026

Monte Rosa Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(24.7)	29.6	(38.2)	(27.8)	(21.0)	129	(45.5)	(34.7)	100	(43.0)	(37.4)	(44.1)
Capital expenditure	$m	1.7	1.7	1.4	2.0	0.4	0.2	1.6	1.7	0.7	0.8	1.9	4.7
Dividends paid	$m	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Diluted shares (weighted)101.48m, Q2 FY2026

Monte Rosa Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	46.7	49.3	49.4	49.8	60.2	71.2	82.0	83.0	82.2	82.4	99.9	101

Shares outstanding: 85.31m at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. Listed shows no prices and gives no investment advice.